Base de dados : MEDLINE
Pesquisa : C04.557.465.625.650 [Categoria DeCS]
Referências encontradas : 6289 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 629 ir para página                         

  1 / 6289 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390385
[Au] Autor:Chin YP; Lai WF; Chiang MT; Chang SC
[Ad] Endereço:Faculty of Medicine, National Yang-Ming University, Taipei.
[Ti] Título:Esophageal neuroendocrine tumor with initial presentation as painless forehead and neck masses: A case report.
[So] Source:Medicine (Baltimore);96(50):e9282, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Esophageal neuroendocrine tumors (NETs) are a rare type of esophageal tumor which are usually positive for chromogranin A, synaptophysin, and CD56 in tumor immunohistochemical staining. The most common symptoms of esophageal NETs are gastrointestinal symptoms such as dysphagia and/or abdominal discomfort. While esophageal NETs have the potential for distant metastasis, there have only been a few reports of brain metastasis originating from esophageal NET. PATIENT CONCERNS: We report the case of a 60-year-old Taiwanese female who initially presented with a 1 month history of painless forehead and bilateral neck masses. She did not complain of any other symptoms, which complicated the diagnosis. DIAGNOSES: Chest and abdominal computed tomography were arranged for a thorough evaluation, and a paraesophageal lesion as well as multiple metastases in the liver, bilateral adrenal glands, and bone were found. Panendoscopy and pathology confirmed the diagnosis of an esophageal NET. INTERVENTIONS: Best supportive care. OUTCOMES: The clinical course of this case deteriorated drastically, and she died of tumor progression 10 days after the diagnosis had been made. LESSONS: To the best of our knowledge, this is the first article in the literature to report a case of esophageal NET whose initial presentation was painless forehead and bilateral neck masses. Clinicians should be aware of the early signs and symptoms of esophageal NET to allow for a prompt diagnosis.
[Mh] Termos MeSH primário: Neoplasias Esofágicas/diagnóstico
Tumores Neuroendócrinos/diagnóstico
[Mh] Termos MeSH secundário: Biópsia
Diagnóstico Diferencial
Diagnóstico por Imagem
Evolução Fatal
Feminino
Testa
Seres Humanos
Meia-Idade
Pescoço
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009282


  2 / 6289 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390320
[Au] Autor:Xu G; Wang P; Xiao Y; Wu X; Lin G
[Ad] Endereço:Department of Liver Surgery.
[Ti] Título:Local resection of rectal neuroendocrine tumor with first clinical manifestation of giant liver metastasis by transanal endoscopic microsurgery: A case report.
[So] Source:Medicine (Baltimore);96(50):e9153, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Rectal neuroendocrine tumor (NET) is a relatively rare tumor. Well-differentiated NETs (G1 and G2) rarely display distant metastasis at initial diagnosis. Currently, treatment for the primary lesions of rectal NETs with liver metastasis remains controversial. The liver metastasis was resected in local hospital. Transanal endoscopic microsurgery (TEM) has emerged as an effective minimally invasive surgery for local resection of lower rectal lesions. Herein, we reported the initial application of TEM to remove the rectal primary lesion in patients with low rectal NETs (G2) with giant liver metastases. PATIENT CONCERNS: The patient, a 45-year-old woman, was primarily diagnosed with hepatocellular carcinoma and underwent curative resection of a giant liver lesion in a local hospital. Nevertheless, the postoperative pathologic examination revealed that the lesion was an NET (G2). The colonoscopy then showed a nodule 1.4 cm in diameter, 4 cm above the anal verge, located on the anterior wall of the rectum. The biopsy revealed that the nodule was also an NET (G2). However, the patient did not consent to abdominoperineal resection based on concerns for quality of life. DIAGNOSES: Rectal NET with liver metastasis. INTERVENTIONS: The patient underwent curative resection of liver metastasis. And, TEM was adopted to resect the primary tumor in rectum. OUTCOMES: The patient has been disease-free for 2 years with a good quality of life and presents no local recurrence in the rectum. LESSONS: TEM is an appropriate palliative operation for therapy of rectal NETs with distant metastases, especially for primary rectal NETs located in low rectal.
[Mh] Termos MeSH primário: Neoplasias Hepáticas/secundário
Neoplasias Hepáticas/cirurgia
Tumores Neuroendócrinos/secundário
Tumores Neuroendócrinos/cirurgia
Neoplasias Retais/patologia
Neoplasias Retais/cirurgia
Microcirurgia Endoscópica Transanal
[Mh] Termos MeSH secundário: Biópsia
Colonoscopia
Feminino
Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009153


  3 / 6289 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448665
[Au] Autor:Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
[Ad] Endereço:Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
[Ti] Título:Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
[So] Source:JAMA Oncol;3(10):1335-1342, 2017 Oct 01.
[Is] ISSN:2374-2445
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: The incidence and prevalence of neuroendocrine tumors (NETs) are thought to be rising, but updated epidemiologic data are lacking. Objective: To explore the evolving epidemiology and investigate the effect of therapeutic advances on survival of patients with NETs. Design, Setting, and Participants: A retrospective, population-based study using nationally representative data from the Surveillance, Epidemiology, and End Results (SEER) program was conducted to evaluate 64 971 patients with NETs from 1973 to 2012. Associated population data were used to determine annual age-adjusted incidence, limited-duration prevalence, and 5-year overall survival (OS) rates. Trends in survival from 2000 to 2012 were evaluated for the entire cohort as well as specific subgroups, including distant-stage gastrointestinal NETs and pancreatic NETs. Analyses were conducted between December 2015, and February 2017. Main Outcomes and Measures: Neuroendocrine tumor incidence, prevalence, and OS rates. Results: Of the 64 971 cases of NETs, 34 233 (52.7%) were women. The age-adjusted incidence rate increased 6.4-fold from 1973 (1.09 per 100 000) to 2012 (6.98 per 100 000). This increase occurred across all sites, stages, and grades. In the SEER 18 registry grouping (2000-2012), the highest incidence rates were 1.49 per 100 000 in the lung, 3.56 per 100 000 in gastroenteropancreatic sites, and 0.84 per 100 000 in NETs with an unknown primary site. The estimated 20-year limited-duration prevalence of NETs in the United States on January 1, 2014, was 171 321. On multivariable analyses, the median 5-year OS rate varied significantly by stage, grade, age at diagnosis, primary site, and time period of diagnosis. The OS rate for all NETs improved from the 2000-2004 period to the 2009-2012 period (hazard ratio [HR], 0.79; 95% CI, 0.73-0.85). Even larger increases in OS between these periods were noted in distant-stage gastrointestinal NETs (HR, 0.71; 95% CI, 0.62-0.81) and distant-stage pancreatic NETs (HR, 0.56; 95% CI, 0.44-0.70). Conclusions and Relevance: The incidence and prevalence of NETs are steadily rising, possibly owing to detection of early-stage disease and stage migration. Survival for all NETs has improved over time, especially for distant-stage gastrointestinal NETs and pancreatic NETs in particular, reflecting improvement in therapies. These data will help to prioritize future research directions.
[Mh] Termos MeSH primário: Neoplasias Gastrointestinais/epidemiologia
Tumores Neuroendócrinos/epidemiologia
Neoplasias Pancreáticas/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Distribuição por Idade
Idoso
Feminino
Neoplasias Gastrointestinais/patologia
Seres Humanos
Incidência
Masculino
Meia-Idade
Tumores Neuroendócrinos/patologia
Neoplasias Pancreáticas/patologia
Prevalência
Estudos Retrospectivos
Programa de SEER
Análise de Sobrevida
Taxa de Sobrevida
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1001/jamaoncol.2017.0589


  4 / 6289 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28746252
[Au] Autor:Thyparampil PJ; Yen MT; Dhingra S; Shetlar DJ; Zarrin-Khameh N; Musher BL
[Ti] Título:Primary Neuroendocrine Tumor of the Orbit Presenting With Acute Proptosis.
[So] Source:Ophthal Plast Reconstr Surg;34(1):e17-e19, 2018 Jan/Feb.
[Is] ISSN:1537-2677
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary neuroendocrine tumors of the orbit are exceedingly rare and typically present with gradual, progressive exophthalmos. In this report, an otherwise healthy 64-year-old woman undergoes resection of a well-differentiated neuroendocrine tumor after presenting with acute proptosis. An extensive clinical and radiographic evaluation reveals no other evidence of disease, establishing the diagnosis of a primary neuroendocrine tumor. The case presentation is followed by a brief review of the classification, presentation, and evaluation of orbital neuroendocrine tumors.
[Mh] Termos MeSH primário: Exoftalmia/etiologia
Tumores Neuroendócrinos/complicações
Órbita/diagnóstico por imagem
Neoplasias Orbitárias/complicações
[Mh] Termos MeSH secundário: Doença Aguda
Exoftalmia/diagnóstico
Exoftalmia/cirurgia
Seres Humanos
Masculino
Meia-Idade
Tumores Neuroendócrinos/diagnóstico
Tumores Neuroendócrinos/cirurgia
Procedimentos Cirúrgicos Oftalmológicos/métodos
Órbita/cirurgia
Neoplasias Orbitárias/diagnóstico
Neoplasias Orbitárias/cirurgia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1097/IOP.0000000000000968


  5 / 6289 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29391119
[Au] Autor:Manguso N; Johnson J; Harit A; Nissen N; Mirocha J; Hendifar A; Amersi F
[Ad] Endereço:Division of Surgical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
[Ti] Título:Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine Tumors.
[So] Source:Am Surg;83(10):1174-1178, 2017 Oct 01.
[Is] ISSN:1555-9823
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Small bowel neuroendocrine tumors (SBNET) account for most gastrointestinal neuroendocrine tumors. Patients often present with late-stage disease; however, there is little information regarding factors that contribute to recurrence. Database review identified 301 patients diagnosed with SBNET between 1990 and 2013. Univariate analysis included patients who underwent complete resection. Survival was estimated by the Kaplan-Meier method. A total of 147 patients met study criteria. Average age was 60 years (range 21-91); 49 per cent were male. Thirty-seven (25.3%) patients had laparoscopic resection, and 29 (19.9%) patients had only small bowel disease, whereas 108 (72.6%) had nodal metastasis. Five-year overall and disease-free survival were 97.5 and 73.5 per cent. Forty-seven (32%) patients had recurrence. The recurrence group was more likely to have an open operation (59.6 vs 32%, P < 0.01), mesenteric invasion, or lymphatic metastasis (87.2 vs 67%, P < 0.01) compared with the no-recurrence group. Cox regression analysis showed that variables associated with recurrence included nodal disease (HR 9.06, P = 0.03), lymphovascular invasion (LVI) (3.95, P < 0.01), perineural invasion (PNI) (3.48, P < 0.01), and mesenteric involvement (3.77, P = 0.03). Patients with SBNET presenting with nodal metastasis, mesenteric involvement, LVI, or PNI have a higher risk of recurrence. Closer surveillance should be considered after operative resection.
[Mh] Termos MeSH primário: Neoplasias Intestinais/cirurgia
Intestino Delgado/cirurgia
Recidiva Local de Neoplasia/etiologia
Tumores Neuroendócrinos/cirurgia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Estudos de Casos e Controles
Bases de Dados Factuais
Feminino
Seguimentos
Seres Humanos
Neoplasias Intestinais/diagnóstico
Neoplasias Intestinais/mortalidade
Neoplasias Intestinais/patologia
Masculino
Meia-Idade
Recidiva Local de Neoplasia/mortalidade
Recidiva Local de Neoplasia/patologia
Tumores Neuroendócrinos/diagnóstico
Tumores Neuroendócrinos/mortalidade
Tumores Neuroendócrinos/patologia
Prognóstico
Fatores de Risco
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE


  6 / 6289 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374682
[Au] Autor:Moris D; Tsilimigras DI; Vagios S; Ntanasis-Stathopoulos I; Karachaliou GS; Papalampros A; Alexandrou A; Blazer DG; Felekouras E
[Ad] Endereço:Department of Surgery, Duke University Medical Center, Duke University, Durham, NC, U.S.A. dimmoris@yahoo.com.
[Ti] Título:Neuroendocrine Neoplasms of the Appendix: A Review of the Literature.
[So] Source:Anticancer Res;38(2):601-611, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Appendiceal neuroendocrine neoplasms (ANENs) comprise rare tumors of the appendix, mainly affecting young populations and characterized by a rather favorable prognosis. The aim of this review was to summarize the current knowledge on these neoplasms, focusing on the management and follow-up of such patients, which still remain under debate. ANENs account for 0.16-2.3% of appendectomies and are usually diagnosed incidentally. The histopathological diagnosis includes the immunohistochemical profile of the tumor in regard to synaptophysin and chromogranin A, as well as the Ki-67 index. The surgical management of ANENs is either simple appendectomy or a more extensive oncological operation including right hemicolectomy. This depends on the stage and the presence of risk factors suggesting a more aggressive disease, such as the exact location, mesoappendiceal or lymphovascular invasion, and the proliferative rate of the tumor. Despite their indolent course, ANENs may relapse. Therefore, lifetime observation is necessary for patients with tumors >2 cm and >1 cm plus additional risk factors; however, more studies should be conducted in order to determine the optimal follow-up strategy.
[Mh] Termos MeSH primário: Neoplasias do Apêndice/patologia
Neoplasias do Apêndice/terapia
Tumores Neuroendócrinos/patologia
Tumores Neuroendócrinos/terapia
[Mh] Termos MeSH secundário: Apendicectomia
Neoplasias do Apêndice/diagnóstico
Neoplasias do Apêndice/epidemiologia
Seres Humanos
Tumores Neuroendócrinos/diagnóstico
Tumores Neuroendócrinos/epidemiologia
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  7 / 6289 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29236425
[Au] Autor:Willenberg V; Bamblett M; Cummins M; Hoberg D
[Ti] Título:Review of a home nursing injection service: SHINE.
[So] Source:Aust Nurs Midwifery J;22(6):30-3, 2014 12.
[Is] ISSN:2202-7114
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:The SHINE home injection service is part of a patient support program run by Novartis. SHINE is for people prescribed octreotide long-acting release (Sandostatin LAR) for neuroendocrine tumours (NETs) and acromegaly. SHINE has been running in Australia since 2009. The service is run by a third-party and administered by homecare (SHINE) nurses. Five hundred people with NETs or acromegaly have been involved since the service started. We review our collective experience of the benefits of SHINE, and make recommendations for future development. We hope this review provides guidance for developing future home injection service.
[Mh] Termos MeSH primário: Acromegalia/tratamento farmacológico
Antineoplásicos Hormonais/administração & dosagem
Assistência Domiciliar
Tumores Neuroendócrinos/tratamento farmacológico
Octreotida/administração & dosagem
[Mh] Termos MeSH secundário: Acromegalia/enfermagem
Austrália
Preparações de Ação Retardada
Esquema de Medicação
Feminino
Seres Humanos
Injeções
Masculino
Tumores Neuroendócrinos/enfermagem
Avaliação de Programas e Projetos de Saúde
[Pt] Tipo de publicação:RESEARCH SUPPORT, NON-U.S. GOV'T; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Delayed-Action Preparations); RWM8CCW8GP (Octreotide)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE


  8 / 6289 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245282
[Au] Autor:Won YG; Seo KJ; Hyeon J; Shin OR; Chang E; Sun S; Won HS; Ko YH; Na SJ; Lee SL; Ku YM; Lee DS
[Ad] Endereço:aDepartment of Radiation OncologybDepartment of Hospital PathologycDivision of Oncology, Department of Internal MedicinedDepartment of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
[Ti] Título:Gastroenteropancreatic-origin neuroendocrine carcinomas: Three case reports with favorable responses following localized radiotherapy and a review of literature.
[So] Source:Medicine (Baltimore);96(49):e9009, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: The radiotherapy (RT) responses of gastroenteropancreatic (GEP)-origin neuroendocrine tumors remain unclear. We report cases of favorable response after localized RT of GEP-origin neuroendocrine carcinomas (GEP-NECs). PATIENT CONCERNS: 1. An 82-year-old male presented with a lower esophageal mass. Positron emission tomography computed tomography (PET-CT) scan showed a lower esophageal mass and gastrohepatic lymph nodes. 2. A 52-year-old female presented with abdominal discomfort. CT scan showed a 9.8 cm-sized enhancing mass in the lesser sac abutting the stomach, pancreas and liver. 3. A 54-year-old male patient presented with anal pain and bleeding. CT scan showed a remnant mass in the perirectal area after trans-anal excision. DIAGNOSES: The diagnoses of GEP-NECs were pathologically confirmed by biopsy or excision, and immunohistochemical stainings of Ki-67, CD56, synaptophysin and chromogranin-A. INTERVENTIONS: 1. The patient was treated with definitive RT. 2. The patient was treated with RT after two cycles of etoposide-cisplatin chemotherapy. 3. The patient was treated with adjuvant RT. OUTCOMES: 1. Complete remission was achieved based on CT scan four months after RT. 2. CT scan showed partial regression of the mass with a 5 cm-diameter at six months after RT. Adjuvant chemotherapy was administered after RT. 3. The residual mass was almost completely regressed at CT scan four months after RT. LESSONS: In cases of GEP-NECs, RT can be a useful treatment modality with favorable tumor response for patients with inoperable conditions or those suffering from bulky tumor masses.
[Mh] Termos MeSH primário: Neoplasias Intestinais/patologia
Neoplasias Intestinais/radioterapia
Tumores Neuroendócrinos/patologia
Tumores Neuroendócrinos/radioterapia
Neoplasias Pancreáticas/patologia
Neoplasias Pancreáticas/radioterapia
Neoplasias Gástricas/patologia
Neoplasias Gástricas/radioterapia
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Quimiorradioterapia Adjuvante/métodos
Feminino
Seres Humanos
Neoplasias Intestinais/diagnóstico
Neoplasias Intestinais/terapia
Masculino
Meia-Idade
Tumores Neuroendócrinos/diagnóstico
Tumores Neuroendócrinos/terapia
Neoplasias Pancreáticas/diagnóstico
Neoplasias Pancreáticas/terapia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Neoplasias Gástricas/diagnóstico
Neoplasias Gástricas/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009009


  9 / 6289 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29232390
[Au] Autor:Koenig A; Krug S; Mueller D; Barth PJ; Koenig U; Scharf M; Ellenrieder V; Michl P; Moll R; Homayunfar K; Kann PH; Stroebel P; Gress TM; Rinke A
[Ad] Endereço:Department of Gastroenterology and Endocrinology, Philipps-University of Marburg, Marburg, Germany.
[Ti] Título:Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.
[So] Source:PLoS One;12(12):e0188876, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chromogranin A (CgA) is a well-established marker for diagnosis and follow up of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). Recently, it has been shown that plasma levels of CgA correlate with tumor load and predict survival of patients with NEN of the small bowel. It is assumed that this is as well valid for NEN of the colon and rectum, however, this is not supported by data. To evaluate this assumption, we analyzed 62 patients with NEN of the colon and rectum listed in the Marburg GEP-NEN registry for clinicopathological characteristics, expression and plasma levels of CgA. The present study demonstrates that immunohistochemical CgA and synaptophysin are good markers for histological diagnosis in patients with NEN of the colon and rectum. However, plasma CgA is a poor marker to follow-up these patients because only a minority exhibited increased levels which did not increase significantly during tumor progression. In contrast to NEN of the small bowel, there is no correlation of CgA plasma levels with tumor burden or survival. Patients with NEN of the colon and rectum displayed a relatively good prognosis resulting in a median survival of 8.5 years. However, a subset of patients affected by G3 neoplasms, exhibited a poorer prognosis with a median survival of 2.5 years. Taken together, CgA is a valuable marker for immunohistochemical diagnosis, but CgA plasma concentration is not suitable to mirror tumor burden or prognosis in patients with NEN of the colon and rectum.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Cromogranina B/sangue
Neoplasias Colorretais/patologia
Tumores Neuroendócrinos/patologia
[Mh] Termos MeSH secundário: Idoso
Neoplasias Colorretais/sangue
Progressão da Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Tumores Neuroendócrinos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Chromogranin B)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188876


  10 / 6289 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29206383
[Au] Autor:Court CM; Ankeny JS; Sho S; Tomlinson JS
[Ti] Título:Circulating Tumor Cells in Gastrointestinal Cancer: Current Practices and Future Directions.
[So] Source:Cancer Treat Res;168:345-76, 2016.
[Is] ISSN:0927-3042
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:GI cancers are the leading cause of cancer-related death worldwide primarily due to a combination of late presentation and aggressive biology. The lack of adequate biomarkers for screening, diagnosis, staging, and prognosis confounds clinical decision-making and delays potentially effective therapies. Circulating tumor cells (CTCs) are a new biomarker with particular promise in GI cancers, potentially offering clinicians and researchers real-time access to tumor tissue in a reliable, safe, and cost-effective manner. Preliminary studies have investigated the potential clinical utility of CTCs for all GI cancer types with promising results. Furthermore, advances in single cell analytics have been successfully applied to CTCs, allowing for exciting new clinical and research applications. In this chapter, we will review the current state of CTC research in GI cancers as well as the potential future applications that are currently being developed.
[Mh] Termos MeSH primário: Neoplasias Gastrointestinais/patologia
Células Neoplásicas Circulantes
[Mh] Termos MeSH secundário: Neoplasias Esofágicas/patologia
Seres Humanos
Tumores Neuroendócrinos/patologia
Neoplasias Pancreáticas/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171221
[Lr] Data última revisão:
171221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE



página 1 de 629 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde